Riot Platforms, Inc. - Quarter Report: 2011 June (Form 10-Q)

appy_10q-063011.htm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2011

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to __________

Commission file number: 001-33675

ASPENBIO PHARMA, INC.

(Exact name of registrant as specified in its charter)

Colorado	84-1553387
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1585 South Perry Street, Castle Rock, Colorado 80104

(Address of principal executive offices) (Zip Code)

(303) 794-2000

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o Accelerated filer o Non-accelerated filer o Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

The number of shares of no par value common stock outstanding as of August 5, 2011 was 8,028,000.

ASPENBIO PHARMA, INC.

		Page
PART I - Financial Information

Item 1.	Condensed Financial Statements

	Balance Sheets as of June 30, 2011 (Unaudited) and December 31, 2010	3

	Statements of Operations for the Three and Six Months Ended June 30, 2011 and 2010 (Unaudited)	4

	Statements of Cash Flows for the Six Months Ended June 30, 2011 and 2010 (Unaudited)	5

	Notes to Condensed Financial Statements (Unaudited)	6

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21

Item 4.	Controls and Procedures	21

PART II - Other Information

Item 1.	Legal Proceedings	22

Item 1A.	Risk Factors	22

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22

Item 6.	Exhibits	23

	Signatures	23

PART I — FINANCIAL INFORMATION

Item 1. Condensed Financial Statements

AspenBio Pharma, Inc.

Balance Sheets

	June 30, 2011 (Unaudited)			December 31, 2010

ASSETS
Current assets:
Cash and cash equivalents	$	6,108,117			$	8,908,080
Short-term investments (Note 1)		951,675				2,932,188
Accounts receivable (Note 7)		20,480				73,176
Inventories, finished goods		1,693				17,130
Prepaid expenses and other current assets		192,644				376,047

Total current assets		7,274,609				12,306,621

Property and equipment, net (Note 2)		2,969,818				3,107,134

Other long term assets, net (Note 3)		1,781,429				1,745,350

Total assets	$	12,025,856			$	17,159,105

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable	$	1,257,327			$	1,126,172
Accrued compensation		22,070				227,570
Accrued expenses		1,150,142				357,685
Notes and other obligations, current portion (Note 4)		107,455				273,861
Deferred revenue, current portion (Note 7)		71,062				746,062

Total current liabilities		2,608,056				2,731,350

Notes and other obligations, less current portion (Note 4)		2,490,379				2,546,682
Deferred revenue, less current portion (Note 7)		598,105				633,636

Total liabilities		5,696,540				5,911,668

Commitments and contingencies (Note 7)

Stockholders' equity (Notes 5 and 6):
Common stock, no par value, 30,000,000 shares authorized;
8,027,665 shares issued and outstanding, each period		66,729,559				66,054,554
Accumulated deficit		(60,400,243	)			(54,807,117	)

Total stockholders' equity		6,329,316				11,247,437

Total liabilities and stockholders' equity	$	12,025,856			$	17,159,105

See Accompanying Notes to Unaudited Condensed Financial Statements

AspenBio Pharma, Inc.

Statements of Operations

Periods Ended June 30,

(Unaudited)

	Three Months Ended								Six Months Ended
	2011				2010				2011				2010
Sales (Note 7)		$	55,322			$	59,132			$	152,638			$	201,265
Cost of sales			2,749				33,960				15,576				99,526

Gross profit			52,573				25,172				137,062				101,739

Other revenue - fee (Note 7)			17,766				16,876				35,531				32,863

Operating expenses:
Selling, general and administrative			1,360,256				2,117,906				2,963,729				4,001,583
Research and development			1,456,335				1,311,235				2,728,330				3,355,432

Total operating expenses			2,816,591				3,429,141				5,692,059				7,357,015

Operating loss			(2,746,252	)			(3,387,093	)			(5,519,466	)			(7,222,413	)

Other income (expense):
Interest income			3,112				11,848				11,359				24,157
Interest expense			(44,152	)			(47,005	)			(89,019	)			(95,430	)
Other, net			—				—				4,000				—

Total other expense			(41,040	)			(35,157	)			(73,660	)			(71,273	)

Net loss		$	(2,787,292	)		$	(3,422,250	)		$	(5,593,126	)		$	(7,293,686	)

Basic and diluted net loss per share		$	(.35	)		$	(.44	)		$	(.70	)		$	(.95	)

Basic and diluted weighted average number
of shares outstanding (Note 1)			8,027,665				7,834,901				8,027,665				7,668,424

See Accompanying Notes to Unaudited Condensed Financial Statements

AspenBio Pharma, Inc.

Statements of Cash Flows

Six Months Ended June 30,

(Unaudited)

	2011				2010
Cash flows from operating activities:
Net loss		$	(5,593,126	)		$	(7,293,686	)
Adjustments to reconcile net loss to
net cash used in operating activities
Stock-based compensation for services			675,005				1,319,676
Depreciation and amortization			252,963				234,889
Amortization of license fee			(35,531	)			(32,863	)
Impairment charges			59,503				56,225
Decrease in:
Accounts receivable			52,696				25,819
Inventories			14,609				63,762
Prepaid expenses and other current assets			183,403				12,896
Increase (decrease) in:
Accounts payable			131,155				(711,464	)
Accrued liabilities			792,457				(107,073	)
Accrued compensation			(205,500	)			(14,332	)
Deferred revenue			(675,000	)			—

Net cash used in operating activities			(4,347,366	)			(6,446,151	)

Cash flows from investing activities:
Purchases of short-term investments			(312,763	)			(3,909,994	)
Sales of short-term investments			2,293,276				545,583
Purchases of property and equipment			(65,128	)			(150,189	)
Patent and trademark acquisition costs			(145,273	)			(235,824	)

Net cash provided by (used in) investing activities			1,770,112				(3,750,424	)

Cash flows from financing activities:
Repayment of notes payable and other obligation			(222,709	)			(54,325	)
Proceeds from exercise of stock warrants and options			—				291,028
Net proceeds from issuance of common stock			—				9,116,529

Net cash (used in) provided by financing activities			(222,709	)			9,353,232

Net decrease in cash and cash equivalents			(2,799,963	)			(843,343	)
Cash and cash equivalents at beginning of period			8,908,080				13,366,777

Cash and cash equivalents at end of period		$	6,108,117			$	12,523,434

Supplemental disclosure of cash flow information:
Cash paid during the period for interest		$	89,314			$	93,110

See Accompanying Notes to Unaudited Condensed Financial Statements

AspenBio Pharma, Inc.

Notes to Condensed Financial Statements

(Unaudited)

INTERIM FINANCIAL STATEMENTS

The accompanying financial statements of AspenBio Pharma, Inc. (the “Company,” “we,” “AspenBio” or “AspenBio Pharma”) have been prepared in accordance with the instructions to quarterly reports on Form 10-Q. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and changes in financial position at June 30, 2011, and for all periods presented have been made. Certain information and footnote data necessary for fair presentation of financial position and results of operations in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted. It is therefore suggested that these financial statements be read in conjunction with the summary of significant accounting policies and notes to financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010. The results of operations for the period ended June 30, 2011, are not necessarily an indication of operating results for the full year.

On July 29, 2011, the Company effected a reverse stock split of its outstanding common stock at a ratio of one-for-five, whereby each five shares of common stock were combined into one share of common stock (the Reverse Stock Split). The Reverse Stock Split was authorized by the Company’s stockholders at the 2011 annual meeting held on July 8, 2011 and approved by the Board of Directors thereafter. The Reverse Stock Split was effective with respect to stockholders of record at the close of business on July 28, 2011, and trading of our common stock on the NASDAQ Capital Market began on a split-adjusted basis beginning on July 29, 2011. As a result of the reverse stock split, each five shares of common stock were combined into one share of common stock and the total number of shares of common stock outstanding was reduced from approximately 40.1 million shares to approximately 8.0 million shares.

All references to shares and share amounts in this quarterly report have been retroactively revised for all periods presented to reflect the Reverse Stock Split, the principal effects of which were to:

reduce the number of shares of common stock issued and outstanding by a factor of 5;

increase the per share exercise price by a factor of 5, and decrease the number of shares issuable upon exercise by a factor of 5, for all outstanding options and warrants entitling the holders to purchase shares of the Company’s common stock; and

proportionately reduce the number of shares authorized and reserved for issuance under the Company’s existing equity compensation plans.

Note 1. Significant Accounting Policies:

Cash, cash equivalents and investments:

The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company’s cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances.

The Company invests excess cash from time to time in highly-liquid debt and equity investments of highly-rated entities which are classified as trading securities. The purpose of the investments is to fund research and development, product development, United States Food and Drug Administration (the “FDA”) approval-related activities and general corporate purposes. Such amounts are recorded at market values using Level 1 inputs in determining fair value and are classified as current, as the Company does not intend to hold the investments beyond twelve months. Investment securities classified as trading are those securities that are bought and held principally for the purpose of selling them in the near term, with the objective of preserving principal and generating profits. These securities are reported at fair value with unrealized gains and losses reported as an element of other income (expense) in current period earnings. The Company’s Board of Directors (the Board) has approved an investment policy covering the investment parameters to be followed with the primary goals being the safety of principal amounts and maintaining liquidity of the fund. The policy provides for minimum investment rating requirements as well as limitations on investment duration and concentrations. Based upon market conditions, the investment guidelines have been tightened to increase the minimum acceptable investment ratings required for investments and shorten the maximum investment term. As of June 30, 2011, 83% of the investment portfolio was in cash equivalents, which is presented as such on the accompanying balance sheet, and the remaining funds were invested in short-term marketable securities with none individually representing more than 10% of the portfolio and none with maturities past June 2012. To date, the Company’s cumulative market loss from the investments has not been significant. For the six months ended June 30, 2011, there was approximately $2,600 in unrealized loss, $1,072 in realized income, and $6,343 in management fees. For the six months ended June 30, 2010, there was approximately $7,149 in unrealized loss, no realized gain or loss, and $8,143 in management fees.

Fair value of financial instruments:

The Company accounts for financial instruments under Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic (ASC) 820 (formerly Statement of Financial Accounting Standard (SFAS) No. 157), Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows:

Level 1 — quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 — observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

Level 3 — assets and liabilities whose significant value drivers are unobservable.

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. There were no financial assets or liabilities measured at fair value, with the exception of cash, cash equivalents and short-term investments as of June 30, 2011 and December 31, 2010.

The carrying amounts of the Company’s financial instruments (other than cash, cash equivalents and short-term investments as discussed above) approximate fair value because of their variable interest rates and / or short maturities combined with the recent historical interest rate levels.

Recently issued and adopted accounting pronouncements:

In October 2009, the FASB issued ASU 2010-13, “Revenue Recognition (Topic 605) — Multiple-Deliverable Revenue Arrangements.” This ASU eliminates the requirement that all undelivered elements must have objective and reliable evidence of fair value before a company can recognize the portion of the consideration that is attributable to items that already have been delivered. This may allow some companies to recognize revenue on transactions that involve multiple deliverables earlier than under the current requirements. Additionally, under the new guidance, the relative selling price method is required to be used in allocating consideration between deliverables and the residual value method will no longer be permitted. This ASU is effective prospectively for revenue arrangements entered into or materially modified beginning in fiscal year 2011. A company may elect, but will not be required, to adopt the amendments in this ASU retrospectively for all prior periods. The adoption of this ASU did not have a material impact on the Company’s financial statements.

In April 2010, the FASB issued ASU 2010-17, “Revenue Recognition – Milestone Method (Topic 605): Milestone Method of Revenue Recognition.” The adoption of this ASU did not have a material impact on the Company’s financial statements.

Income (loss) per share:

ASC 260 (formerly - SFAS No. 128), Earnings Per Share, requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.

Basic earnings (loss) per share includes no dilution and is computed by dividing net earnings (loss) available to stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the Company’s earnings (loss). The effect of the inclusion of the dilutive shares would have resulted in a decrease in loss per share. Accordingly, the weighted average shares outstanding have not been adjusted for dilutive shares. Outstanding stock options and warrants are not considered in the calculation, as the impact of the potential common shares (totaling approximately 1,287,400 shares as of June 30, 2011, and approximately 1,297,600 shares as of June 30, 2010) would be to decrease loss per share.

A reconciliation of basic and diluted weighted average number of shares outstanding adjusted for the Reverse Stock Split follows:

	Three Months Ended				Six Months Ended
	2011		2010		2011		2010
Basic and diluted weighted average number of shares outstanding:
Pre-split		40,138,324		39,174,507		40,138,324	38,342,121
Post split		8,027,665		7,834,901		8,027,665	7,668,424

Note 2. Property and Equipment:

Property and equipment consisted of the following:

	June 30, 2011 (Unaudited)		December 31, 2010

Land and improvements	$	1,107,508	$	1,107,508
Building		2,589,231		2,589,231
Building improvements		251,049		235,946
Laboratory equipment		1,156,974		1,207,241
Office and computer equipment		393,770		378,431
		5,498,532		5,518,357
Less accumulated depreciation		2,528,714		2,411,223
	$	2,969,818	$	3,107,134

Note 3. Other Long Term Assets:

Other long term assets consisted of the following:

	June 30, 2011 (Unaudited)		December 31, 2010
Patents and trademarks and applications, net of
accumulated amortization of $238,494 and $190,829, respectively	$	1,381,670	$	1,342,737
Goodwill		387,239		387,239
Other		12,520		15,374
	$	1,781,429	$	1,745,350

The Company capitalizes legal costs and filing fees associated with obtaining and maintaining patents on its new discoveries. Once the patents have been issued, the Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life using the straight-line method. Based upon the current status of the above intangible assets, the aggregate amortization expense is estimated to be approximately $60,000 for each of the next five fiscal years.

Note 4. Notes and Other Obligations:

Notes payable and other obligation consisted of the following:

	June 30, 2011 (Unaudited)		December 31, 2010

Mortgage notes	$	2,597,834		$	2,653,737
Other installment obligations		—			166,806
		2,597,834			2,820,543
Less current portion		107,455			273,861
	$	2,490,379		$	2,546,682

Mortgage notes:

The Company has a mortgage facility on its land and building. The mortgage is held by a commercial bank and includes approximately 35% that is guaranteed by the U. S. Small Business Administration (SBA). The loan is collateralized by the real property and is also personally guaranteed by a stockholder of the Company. The interest rate on the bank portion is one percentage over the Wall Street Journal Prime Rate (minimum 7%), with 7% being the approximate effective rate, and the SBA portion bears interest at the rate of 5.86%. The commercial bank portion of the loan requires total monthly payments of approximately $14,200, which includes approximately $9,800 per month in contractual interest, through June 2013 when the then remaining principal balance is due and which is estimated to be approximately $1,607,000 at that time. The SBA portion of the loan requires total monthly payments of approximately $9,200 through July 2023, which includes approximately $4,400 per month in contractual interest and fees.

Future maturities:

The Company’s debt obligations require minimum annual principal payments of approximately $51,000 for the remainder of 2011, $114,000 in 2012, $1,670,000 in 2013, $65,000 in 2014, $68,000 in 2015, and $630,000 thereafter, through the terms of the agreements. The Company’s Exclusive License Agreement with The Washington University also requires minimum annual royalty payments of $20,000 per year during its term.

Note 5. Stockholders’ Equity:

Upon the completion of the 2011 annual shareholder meeting on July 8, 2011, the Board of Directors approved an amendment to the Company’s Articles of Incorporation to reduce the authorized common shares from 60 million to 30 million. The approval also authorized a 1-for-5 reverse stock split of the Company’s common stock that the Board implemented as of July 29, 2011. All common stock and per share amounts in this Quarterly Report on Form 10-Q have been retroactively revised to reflect the reverse stock split. No fractional shares will be issued or purchased as each fraction that results from the reverse split will be rounded up to the nearest whole share.

During the six months ended June 30, 2011, there were no exercises of stock options. During the six months ended June 30, 2010, advisors exercised options under the Company’s 2002 Stock Incentive Plan to purchase 52,209 shares of common stock generating $291,028 in cash proceeds to the Company.

In May 2010, the Company completed a registered direct offering consisting 481,928 “Units” for a negotiated price of $20.75 per Unit, generating approximately $9,117,000 in net proceeds to the Company. Fees and expenses totaled $883,000, including a placement fee of 6.5%. Each Unit consisted of one share of the Company’s no par value common stock and one warrant to purchase 0.285 shares of common stock. Accordingly, a total 481,928 common shares and warrants to purchase 137,349 shares were issued. The exercise price of the warrants was $24.10 per common share and the warrants were exercisable upon issuance for an eight month term and expired in January 2011.

Note 6. Stock Options and Warrants:

Stock options:

The Company currently provides stock-based compensation to employees, directors and consultants under the Company’s 2002 Stock Incentive Plan, as amended (Plan). In July 2011, the Company’s shareholders approved an amendment to the Plan to increase the number of shares reserved under the Plan from 1,360,000 to 1,500,000. The Company estimates the fair value of the share-based awards on the date of grant using the Black-Scholes option-pricing model (the “Black-Scholes model”). Using the Black-Scholes model, the value of the award that is ultimately expected to vest is recognized over the requisite service period in the statement of operations. Option forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company attributes compensation to expense using the straight-line single option method for all options granted.

The Company’s determination of the estimated fair value of share-based payment awards on the date of grant is affected by the following variables and assumptions:

▪	The grant date exercise price – the closing market price of the Company’s common stock on the date of the grant;
▪	Estimated option term – based on historical experience with existing option holders;
▪	Estimated dividend rates – based on historical and anticipated dividends over the life of the option;
▪	Term of the option – based on historical experience, grants have lives of approximately 5 years;
▪	Risk-free interest rates – with maturities that approximate the expected life of the options granted;
▪	Calculated stock price volatility – calculated over the expected life of the options granted, which is calculated based on the daily closing price of the Company’s common stock over a period equal to the expected term of the option; and
▪	Option exercise behaviors – based on actual and projected employee stock option exercises and forfeitures.

The Company utilized assumptions in the estimation of fair value of stock-based compensation for the six months ended June 30 as follows:

	2011		2010

Dividend yield		0%		0%
Expected price volatility		119 to 120%		110 to 115%
Risk free interest rate		1.55 to 2.14%		2.06 to 2.62%
Expected term	5 years		5 years

The Company recognized total expenses for stock-based compensation during the periods ended June 30, as follows:

	Three Months Ended				Six Months Ended
	2011		2010		2011		2010
Stock options to employees and directors	$	245,158	$	677,830	$	609,443	$	1,095,754
Stock options to consultants for:
Animal health activities		7,190		16,003		14,380		49,465
AppyScore activities		22,453		8,658		34,326		113,283
Investor relations activities		16,856		22,433		16,856		61,174

Total stock-based compensation	$	291,657	$	724,924	$	675,005	$	1,319,676

The above expenses are included in the accompanying Statements of Operations for the periods ended June 30, in the following categories:

	Three Months Ended				Six Months Ended
	2011		2010		2011		2010
Selling, general and administrative expenses	$	269,204	$	724,924	$	640,679	$	1,319,676
Research and development expenses		22,453		—		34,326		—

Total stock-based compensation	$	291,657	$	724,924	$	675,005	$	1,319,676

A summary of stock option activity under the Company’s Plan for options to employees, officers, directors and consultants, for the six months ended June 30, 2011, is presented below:

	Shares Underlying Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value

Outstanding at January 1, 2011	1,103,358		$	10.60
Granted	193,100			3.06
Exercised	—			—
Forfeited	(111,067	)		8.70

Outstanding at June 30, 2011	1,185,391		$	9.56	7.0	$	42,000

Exercisable at June 30, 2011	726,797		$	10.94	5.8	$	—

The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company’s closing stock price on June 30, 2011 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders, had all option holders been able to, and in fact had, exercised their options on June 30, 2011.

During the six months ended June 30, 2011, 193,100 stock options were granted under the Plan to employees, officers, directors, and consultants with a weighted average fair value at the grant date of $3.06 per option. Included in the 193,100 options issued, existing directors and officers were granted a total of 125,000 options at an exercise price of $2.95 per share and existing employees were granted 25,900 options at an exercise price of $3.05 per share, all vesting over a three-year period annually in arrears and expiring in ten years. Three newly hired employees were granted a total of 2,200 options at $3.30 per share, all vesting over a three-year period annually in arrears and expiring in ten years. The Company also issued 40,000 non-qualified options to a consultant at an exercise price of $3.40 per share which expire in ten years. These non-qualified options are performance related with vesting tied to achieving specific AppyScore clinical and regulatory milestones.

During the six months ended June 30, 2011, a total of 111,067 options that were granted under the Plan were forfeited, 61,800 of which were vested and 49,267 which were unvested. The options were exercisable at an average of $8.70 per share and were forfeited upon the employees’ terminations from the Company. During the six months ended June 30, 2011, no options were exercised.

During the six months ended June 30, 2010, 261,500 stock options were granted under the Plan to employees, officers, directors and consultants exercisable at the then market price which averaged $11.11 per share, a weighted average fair value at the grant date of $8.85 per option. Existing directors and officers were granted a total of 135,000 options at $11.00 per share and existing employees were granted 23,700 options at $10.95 per share, all vesting over a three-year period annually in arrears and expiring in ten years. The Company also issued 80,000 options to a newly hired officer exercisable at $11.40 per share which vest over a three-year period annually in arrears and expire in ten years. Out of these 80,000 options, vesting of 20,000 options was accelerated, under their terms when performance achievements were reached. A consultant was granted 8,000 options at $10.20 per share vesting in equal amounts after six months, twelve months, twenty-four months and thirty-six months from the date of grant and expiring in ten years and a consultant was granted 10,000 options at $11.15 per share vested at the grant date and expiring in five years. Four newly-hired employees were granted a total of 4,800 options at an average exercise price of $10.05 per share, all vesting over a three-year period annually in arrears and expiring in ten years.

During the six months ended June 30, 2010, advisors exercised 52,209 options outstanding under the Company’s Plan generating $291,028 in cash and which had an intrinsic value when exercised of $371,130. During the six months ended June 30, 2010, a total of 3,600 options were forfeited, 2,000 of which were vested and 1,600 were unvested. The options were exercisable at an average of $10.50 per share and were forfeited upon the employees’ terminations from the Company.

The total fair value of stock options granted to employees, officers, directors and consultants that vested and became exercisable during the six months ended June 30, 2011 and 2010, was $1,679,000 and $1,631,000, respectively. Based upon the Company’s experience, approximately 85% of the outstanding stock options, or approximately 1,008,000 options, are expected to vest in the future, under their terms.

A summary of the activity of non-vested options under the Company’s Plan to acquire common shares granted to employees, directors and consultants during the six months ended June 30, 2011, is presented below:

Nonvested Shares	Nonvested Shares Underlying Options			Weighted Average Exercise Price		Weighted Average Grant Date Fair Value
Nonvested at January 1, 2011		506,063		$	10.80	$	8.35
Granted		193,100			3.06		2.53
Vested		(191,301	)		11.83		8.78
Forfeited		(49,267	)		8.62		7.05
Nonvested at June 30, 2011		458,595		$	7.37	$	5.84

At June 30, 2011, based upon employee, officer, director and consultant options granted to that point, there was approximately $1,443,000 of additional unrecognized compensation cost related to stock options that will be recorded over a weighted average future period of approximately two years.

Subsequent to June 30, 2011, two officers of the Company were granted a total of 120,000 options as retention awards at an exercise price of $3.40 per share all vesting over a three-year period annually in arrears and expiring in ten years.

Other common stock purchase options and warrants:

As of June 30, 2011, in addition to the stock options discussed above, the Company had outstanding 102,000 non-qualified options and warrants in connection with an officer’s employment, investor relation consulting services and placement agent services.

The Company utilized assumptions in the estimation of fair value of stock-based compensation for the six month periods ended June 30 as follows:

	2011		2010

Dividend yield		0%		0%
Expected price volatility		119 to 145%		128 to 130%
Risk free interest rate		1.20 to 1.95%		1.26 to 1.70%
Contractual term	3-5 years		3 years

Operating expenses for the three months ended June 30, 2011 and 2010 include $25,807 and $38,741, respectively, for the value of the non-qualified options. Operating expenses for the six months ended June 30, 2011 and 2010 include $33,267 and $61,174, respectively, for the value of the non-qualified options.

Following is a summary of such outstanding options and warrants for the six months ended June 30, 2011:

	Shares Underlying Options/Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value

Outstanding at January 1, 2011	182,855		$	25.15
Granted	70,000			4.00
Exercised	—			—
Forfeited	(150,855	)		26.42
Outstanding at June 30, 2011	102,000		$	8.75	4.8	$	—

Exercisable at June 30, 2011	39,500		$	16.45	1.1	$	—

During the six months ended June 30, 2011, the Company hired a Vice President of Marketing and Business who previously had a consulting relationship with the Company. As part of the employment arrangement, the Board approved an employment-inducement grant made outside of the Company’s Stock 2002 Incentive Plan, and he was granted 40,000 options for services which are exercisable at $3.25 per share. The options vest equally over a three year period on the first, second and third anniversary of the grant date and expire in ten years. Also, during the six months ended June 30, 2011, an investor relations firm was granted 30,000 warrants to purchase shares of common stock which are scheduled to vest at 2,500 shares per month over the twelve months from the date of grant and are exercisable at $5.00 per share and expire in three years. During the six months ended June 30, 2011, 13,506 investor relations consultant options were forfeited of which 9,000 were exercisable at $60.00 per share and 4,506 options were exercisable at $30.05 per share. In addition 137,349 warrants granted at $24.10 per share in connection with the 2010 public registered direct offering expired.

The total fair value of stock options granted to an officer and an investor relations consultant that vested and became exercisable during the six months ended June 30, 2011 was $20,227.

A summary of the activity of non-vested, non-qualified options and warrants in connection with employment, investor relations consulting services and placement agent services during the six months ended June 30, 2011, is presented below:

Nonvested Shares	Nonvested Shares Underlying Options			Weighted Average Exercise Price		Weighted Average Grant Date Fair Value

Nonvested at January 1, 2011		—		$	—	$	—
Granted		70,000			4.00		2.69
Vested		(7,500	)		5.00		2.70
Forfeited		—			—		—
Nonvested at June 30, 2011		62,500		$	3.88	$	2.69

At June 30, 2011, there was approximately $155,000 in unrecognized cost for non-qualified options and warrants that will be recorded over a weighted average future period of approximately two years.

Subsequent to June 30, 2011, 6,000 investor relations options expired, 3,000 were exercisable at $30.05 per share and 3,000 were exercisable at $27.85 per share.

Note 7. Concentrations, Commitments and Contingencies:

Customer concentration:

At June 30, 2011, one customer accounted for approximately 98% of total accounts receivable. For the six months ended June 30, 2011, four customers represented more than 10% of the Company’s sales, accounting for approximately 21%, 20%, 13%, and 11% respectively, of the sales for the period. For the three months ended June 30, 2011, two customers represented more than 10% of the Company’s sales, accounting for approximately 55% and 26% respectively, of the sales for the period. At December 31, 2010, two customers accounted for 63% and 20% of total accounts receivable. For the six months ended June 30, 2010, five customers represented more than 10% of the Company’s sales, accounting for approximately 17%, 15%, 15%, 12% and 10%, respectively, of the sales for the period. For the three months ended June 30, 2010, four customers represented more than 10% of the Company’s sales, accounting for approximately 24%, 15%, 14% and 12%, respectively, of the sales for the period.

Commitments:

In April 2008, the Company entered into a long-term exclusive license and commercialization agreement with Novartis Animal Health, Inc. (“Novartis” or “NAH”), to develop and launch the Company’s novel recombinant single-chain products for use in bovines, BoviPure LH™ and BoviPure FSH™. The Exclusive License Agreement (Novartis License Agreement) between AspenBio and Novartis was effective April 2, 2008, and grants Novartis a license to AspenBio technology and a sublicense to The Washington University (WU) technology for use in bovine species products worldwide. The term of the Novartis License Agreement continues until the expiration of the last-to-expire of the licensed patent rights, product sales are terminated, or, generally, ten years after the initial product sales if licensed patent rights are not available on a country-by-country basis. The Novartis License Agreement provides that Novartis and AspenBio share development expenses and product sales margins under a splitting arrangement. AspenBio’s share of development expenses is in the low double-digit range. AspenBio’s share of the product sales margins varies depending upon the level of patent protection and competition on a country-by-country basis and varies from the very low to low double-digit range.

AspenBio received an upfront cash payment of $2,000,000 under the Novartis License Agreement of which 50% was non-refundable upon signing the agreement, and the balance is subject to certain conditions. In 2010, the conditions associated with $100,000 of such milestones were satisfied. Novartis has the right to request a refund of the $900,000 remaining milestone payment and/or terminate the agreement if the pilot study (as defined in the agreement) is not successful. This pilot study was completed during late 2010. Novartis has informed the Company that preliminary pilot study results revealed failure of the pilot study to demonstrate the outcomes as defined in the success criteria, and Novartis has requested a refund of the $900,000 milestone payment. During the six months ended June 30, 2011, the remaining unachieved milestone payment of $900,000 has been reclassified from the current portion of deferred revenue into accrued expenses as a current liability. We received the final, detailed report of the pilot study from Novartis and are in the process of reviewing it. Novartis has indicated that they would defer the refund request until we have had an opportunity to review the final report. We plan to work with Novartis to obtain additional information and understand the implications of the pilot study results on product development efforts under the Novartis License Agreement.

The Novartis License Agreement contains customary terms for confidentiality, prosecution and infringement provisions for the license patent rights, indemnification and insurance coverage. The Novartis License Agreement is cancelable by Novartis on 180 days advance notice; immediately if a change in control transaction occurs and Novartis’ rights are not accommodated in good faith by the successor entity; or on 30 days notice on a country-by-country basis in the event designated legal or regulatory issues arise. AspenBio can terminate the agreement immediately if Novartis challenges the validity or enforceability of licensed patent rights or other licensed intellectual property. Either party may terminate if the other party materially breaches the Novartis License Agreement, and fails to cure such breach, becomes insolvent or if either party disposes of substantially all of the assets necessary for its performance under the terms of the agreement. In the event there is a change of ownership in AspenBio, Novartis may choose to assume all obligations under the agreement and generally remit net excess royalty amounts to the successor entity.

In 2004, the Company entered into an agreement with WU, under which the Company obtained exclusive proprietary rights to WU’s patent portfolio for use in the animal health industry. The Exclusive License Agreement (WU License Agreement) was entered into effective May 1, 2004, and grants AspenBio an exclusive license and right to sublicense WU’s technology (as defined under the WU License Agreement) for veterinary products worldwide, except where such products are prohibited for export under U.S. laws. The term of the WU License Agreement continues until the expiration of the last of WU’s licensed patents expire. AspenBio has agreed to pay minimum annual royalties of $20,000 during the term of the WU License Agreement and such amounts are creditable against future royalties. Royalties payable to WU under the WU License Agreement for covered product sales by AspenBio carry a mid-single digit royalty rate, and for sublicense fees received by AspenBio, carry a low double-digit royalty rate. The WU License Agreement contains customary terms for confidentiality, prosecution and infringement provisions for licensed patents, publication rights, indemnification and insurance coverage. The WU License Agreement is cancelable by AspenBio with ninety days advance notice at any time and by WU with sixty days advance notice if AspenBio materially breaches the WU License Agreement and fails to cure such breach. Under the terms of the WU License Agreement, a portion of license fees and royalties AspenBio receives from sublicensing agreements will be paid to WU. The obligation for such front end fees, totaling $440,000, was recorded upon receipt of the Novartis license fees and, in 2008; $190,000 was paid to WU.

Revenue recognition related to the Novartis License Agreement and WU Agreement is based primarily on the Company’s consideration of Accounting Standards Codification No. 808-10-45 (EITF 07-1), “Accounting for Collaborative Arrangements”, paragraphs 16-20. For financial reporting purposes, the up-front license fees received from the Novartis License Agreement, net of the amounts due to WU, have been recorded as deferred revenue and are amortized over the term of the Novartis License Agreement. Milestone revenue was recognized into income commencing with the date such milestones are achieved. During the year ended December 31, 2010, milestones totaling $100,000 were achieved, triggering the commencement of amortization of $100,000 of deferred revenue. As of June 30, 2011, deferred revenue of $71,062 has been classified as a current liability and $598,105 has been classified as a long-term liability. The current liability includes the next twelve months’ portion of the amortizable milestone revenue. During the six months ended June 30, 2011 and 2010, $35,531 and $32,863, respectively, was recorded as the amortized license fee revenue arising from the Novartis License Agreement.

A tabular summary of the milestone categories and amounts of deferred revenue / revenue recognition follows:

Category	Non-refundable			Milestone Contingent			Total

Prepaid by Novartis	$	1,000,000		$	1,000,000		$	2,000,000
Due to WU	$	(190,000	)	$	(250,000	)	$	(440,000	)
Net carrying amounts at signing	$	810,000		$	750,000		$	1,560,000
Milestones achieved in 2010	$	100,000		$	(100,000	)	$	-
Reclassification	$	-			(750,000	)	$	(750,000	)
Revenue amortization to June 30, 2011	$	(215,833	)	$	-		$	(215,833	)
Net carrying amounts at June 30, 2011	$	669,167		$	-		$	699,167
Commencement of revenue recognition	Upon signing / milestone achievement			Upon milestone achievement

Original amortization period	152 months			T/B/D upon milestone achievement over remaining life

As of June 30, 2011, the Company has employment agreements with four officers providing aggregate annual minimum commitments totaling $875,000. The agreements automatically renew at the end of each year unless terminated by either party and contain customary confidentiality and benefit provision.

Contingencies:

On September 1, 2010, the Company received a complaint, captioned Mark Chipman v. AspenBio Pharma, Inc., Case No. 2:10-cv-06537-GW -JC. The complaint was filed in the United States District Court in the Central District of California by an individual investor. The complaint includes allegations of fraud, negligent misrepresentation, violations of Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”) and Securities and Exchange Commission (“SEC”) Rule 10b-5, and violations of Sections 25400 and 25500 of the California Corporations Code, all related to the Company’s blood-based acute appendicitis test in development known as AppyScore. On the Company’s motion, the action was transferred to the U.S. District Court for the District of Colorado by order dated January 21, 2011. The action has been assigned a District of Colorado Civil Case No. 11-cv-00163-REB-KMT. Based on a review of the currently operative complaint, the Company believes that the plaintiff’s allegations are without merit, and intends to vigorously defend against these claims. The plaintiff may file an amended complaint on or about August 10, 2011, after which time the Company anticipates filing a motion to dismiss the case. If the plaintiff does not file an amended complaint, the Company expects that it will renew its pending motion to dismiss.

On October 1, 2010, the Company received a complaint, captioned John Wolfe, individually and on behalf of all others similarly situated v. AspenBio Pharma, Inc. et al., Case No. CV10 7365. This federal securities purported class action was filed in the United States District Court in the Central District of California on behalf of all persons, other than the defendants, who purchased common stock of AspenBio Pharma, Inc. during the period between February 22, 2007 and July 19, 2010, inclusive. The complaint names as defendants certain officers and directors of the Company during such period. The complaint includes allegations of violations of Section 10(b) of the Exchange Act and SEC Rule 10b-5 against all defendants, and of Section 20(a) of the Exchange Act against the individual defendants, all related to the Company’s blood-based acute appendicitis test in development known as AppyScore. On the Company’s motion, this action was also transferred to the U.S. District Court for the District of Colorado by order dated January 21, 2011. The action has been assigned a District of Colorado Civil Case No. 11-cv-00165-REB-KMT. On July 11, 2011, the court appointed a lead plaintiff to represent the purported class. The lead plaintiff is expected to file an amended complaint on or about August 10, 2011, after which time the Company anticipates filing a motion to dismiss the case. If the plaintiff does not file an amended complaint, the Company expects to renew its pending motion to dismiss. Based on a review of the plaintiff’s currently operative complaint, the Company and the individual defendants believe that the plaintiff’s allegations are without merit, and intend to vigorously defend against these claims.

On January 4, 2011, a plaintiff filed a complaint in the U.S. District Court for the District of Colorado captioned Frank Trpisovsky v. Pusey, et al., Civil Action No. 11-cv-00023-PAB-BNB, that purports to be a shareholder derivative action on behalf of the Company against thirteen individual current or former officers and directors. The complaint also names the Company as a nominal defendant. The plaintiff asserts violations of Section 14(a) of the Exchange Act, SEC Rule 14a-9, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. On motion of the Company and the individual defendants, the U.S. District Court has stayed this derivative action by order dated March 15, 2011. The Company believes that the plaintiff lacks standing to proceed with this action and intends to challenge the plaintiff’s standing if and when the stay is lifted.

In the ordinary course of business and in the general industry in which the Company is engaged, it is not atypical to periodically receive a third party communication which may be in the form of a notice, threat, or ‘cease and desist’ letter concerning certain activities. For example, this can occur in the context of the Company’s pursuit of intellectual property rights. This can also occur in the context of operations such as the using, making, having made, selling, and offering to sell products and services, and in other contexts. The Company intends to make a rational assessment of each situation on a case-by-case basis as such may arise. The Company periodically evaluates its options for trademark positions and considers a full spectrum of alternatives for trademark protection and product branding.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Results of Operations:

Comparative Results for the Six Months Ended June 30, 2011 and 2010

Sales of the Company’s antigen products for the six months ended June 30, 2011 totaled $153,000, which is a $49,000 or 24% decrease from the 2010 period. The decrease in sales is primarily attributable to the Company’s strategic decision to suspend antigen production in 2010 and focus available scientific resources on the appendicitis and single-chain animal product developments.

In April 2008, the Company entered into a long term exclusive license and commercialization agreement with Novartis to develop and launch the Company’s novel recombinant single-chain products for bovine species. The total payments received under this agreement were recorded as deferred revenue and are being recognized over future periods, with $36,000 and $33,000 of such license fee recognized in each of the six months ended June 30, 2011 and 2010.

Cost of sales for the six months ended June 30, 2011 totaled $16,000 which is an $84,000 or 84% decrease as compared to the 2010 period. As a percentage of sales, gross profit in the six months ended June 30, 2011 was 90% as compared to gross profit of 51% in the 2010. The improvement in the gross profit percentage resulted from no fixed production costs incurred in the 2011 period.

Selling, general and administrative expenses in the six months ended June 30, 2011, totaled $2,964,000, which is a $1,038,000 or 26% decrease as compared to the 2010 period. Total stock-based compensation and non-qualified option expenses decreased $635,000 in the 2011 period, primarily due to fewer options being granted combined with lower computed Black-Scholes values attributable to the options granted. Additionally, employee incentives decreased $211,000 as no amount was accrued for in the 2011 period. Expenses associated with public company activities were approximately $191,000 lower in the 2011 period.

Research and development expenses in the 2011 period totaled $2,728,000, which is a $627,000 or 19% decrease as compared to the 2010 period. The completion of the ELISA- based appendicitis clinical trial in mid-2010 resulted in a $1,246,000 decrease which was offset by $283,000 in AppyScore pre-clinical trial costs incurred for the six months ended June 30, 2011. Current efforts related to the appendicitis test development and research increased expenses by approximately $380,000 compared to the 2010 period. Expenses incurred for the single-chain animal product development decreased by approximately $44,000 in the 2011 period following completion of the bovine pivotal trial in 2010.

Primarily as a result of lower average cash and investment returns in 2011 as compared to 2010, interest income of approximately $11,000 was earned in 2011 as compared to $24,000 in 2010.

No income tax benefit was recorded on the loss for the six months ended June 30, 2011, as management was unable to determine that it was more likely than not that such benefit would be realized.

Comparative Results for the Three Months Ended June 30, 2011 and 2010

Sales for the three months ended June 30, 2011 totaled $55,000, which is a $4,000 or 6% decrease from the 2010 period. The decrease in sales is primarily attributable to the Company’s strategic decision to suspend antigen production in 2010 and focus available scientific resources on the appendicitis and single-chain animal product developments.

In April 2008, the Company entered into a long term exclusive license and commercialization agreement to develop and launch the Company’s novel recombinant single-chain bovine products. The total payments received under this agreement were recorded as deferred revenue and will be recognized in the future, with $18,000 and $17,000 of such license fee recognized in each of the respective three month periods ended June 30, 2011 and 2010.

Cost of sales for the three months ended June 30, 2011 totaled $3,000, which is a $31,000 or 92% decrease as compared to the 2010 period. As a percentage of sales, gross profit was 95% in the 2011 period as compared to gross profit of 43% in the 2010 period. The improvement in the gross profit percentage resulted from no fixed production cost incurred in the 2011 period.

Selling, general and administrative expenses in the three months ended June 30, 2011, totaled $1,360,000, which is a $758,000 or 36% decrease as compared to the 2010 period. Total stock-based compensation and non-qualified option expenses decreased $433,000 in the 2011 period, primarily due to fewer options being granted combined with lower computed Black-Scholes values attributable to the options granted. Additionally, employee incentives decreased $167,000 as no amount was accrued for in the 2011 period. Expenses associated with public company activates were approximately $48,000 lower in the 2011 period.

Research and development expenses in the three months ended June 30, 2011, totaled $1,456,000, which is a $145,000 or 11% increase as compared to the 2010 period. The completion of the ELISA based appendicitis clinical trial in mid-2010 resulted in an $85,000 decrease in the 2011 period which was offset by $116,000 increase in AppyScore pre-clinical trial costs and an $112,000 increase in appendicitis secondary marker development research for the three month period ended June 30, 2011.

Primarily as a result of the lower levels of cash and reduced investment returns in 2011 as compared to 2010, interest income of approximately $3,000 was earned in 2011 as compared to $12,000 in 2010.

Liquidity and Capital Resources

At June 30, 2011, we had working capital of $4,667,000 which included cash, cash equivalents and short term investments of $7,060,000. We reported a net loss of $5,593,000 during the six months ended June 30, 2011, which included $952,000 in non-cash expenses relating to stock-based compensation of $675,000 and $277,000 for depreciation, amortization and impairment charges.

Currently, our primary focus is to continue the development activities on our acute appendicitis diagnostic test, including advancement of such test with the FDA, and development of animal health single-chain products to attempt to secure near-term value from these products.

We expect to continue to incur losses from operations for the near-term and these losses could be significant as we incur product development, contract consulting and other product development related expenses. We are closely monitoring our cash balances, cash needs and expense levels. We are likely to need to generate additional capital within the next twelve months. We have recently filed a shelf registration statement that could facilitate a funding and also are exploring alternative methods of raising cash. We believe that our current working capital position will be sufficient to meet our estimated cash needs for the remainder of 2011. Our investments are maintained in short term, high quality investment instruments, to ensure we have ready access to cash as needed. The accompanying financial statements do not include any adjustments that might result from the outcome of this funding uncertainty.

Capital expenditures, primarily for production, laboratory and facility improvement costs for the fiscal year ending December 31, 2011 are anticipated to total $200,000 to $300,000. We anticipate these capital expenditures to be financed through working capital.

We anticipate that expenditures for research and development for the fiscal year ending December 31, 2011 will in total be higher as compared to the amounts expended in 2010, primarily due to expected work on pre-clinical and clinical trials. Development and testing costs in support of the current pipeline products as well as costs to file patents and revise and update previous filings on our technologies will continue to be substantial. Our principal development products consist of the AppyScore test and the single-chain animal-health hormone products. As we continue towards commercialization of these products, including evaluation of alternatives for possible product management and distribution alternatives and implications of product manufacturing and associated carrying costs such evaluation and related decisions will impact our future capital needs. Certain costs such as manufacturing and license / royalty agreements have different financial, logistical and operational implications depending upon the ultimate strategic commercialization path determined.

We expect that our primary development expenditures will be to continue to advance product development and testing of the cassette and instrument version of AppyScore. During the six months ended June 30, 2011 and 2010, we expended approximately $1,409,000 and $2,376,000, respectively, in direct costs for the acute appendicitis test development and related efforts. Steps to achieve commercialization of the acute appendicitis product will be an ongoing and evolving process with subsequent generations and expected improvements being made in the test. Should we be unable to achieve FDA clearance of the AppyScore appendicitis test and generate revenues from the product, we would need to rely on other product opportunities to generate revenues and costs that we have incurred for the acute appendicitis patent may be deemed impaired.

In April 2008, the Company entered into a long-term exclusive license and commercialization agreement with Novartis Animal Health, Inc., to develop and launch the Company’s novel recombinant single-chain products for use in bovines, BoviPure LH™ and BoviPure FSH™. The Exclusive License Agreement between AspenBio and Novartis was effective April 2, 2008 and grants Novartis a license to AspenBio technology and a sublicense to The Washington University (WU) technology (each as defined under the Novartis License Agreement) for use in bovine species products worldwide. The term of the Novartis License Agreement continues until the expiration of the last-to-expire of the licensed patent rights, product sales are terminated or, generally, ten years after the initial product sales if licensed patent rights are not available on a country-by-country basis. The Novartis License Agreement provides that Novartis and AspenBio share development expenses and product sales margins under a splitting arrangement. AspenBio’s share of development expenses is in the low double-digit range. AspenBio’s share of the product sales margins varies depending upon the level of patent protection and competition on a country-by-country basis and varies from the very low to low double-digit range.

AspenBio received an upfront cash payment of $2,000,000 under the Novartis License Agreement of which 50% was non-refundable upon signing the agreement, and the balance is subject to certain conditions. In 2010, the conditions associated with $100,000 of such milestones were satisfied. Novartis has the right to request a refund of the $900,000 remaining milestone payment and/or terminate the agreement if the pilot study (as defined in the agreement) is not successful. This pilot study was completed during late 2010. Novartis has informed us that preliminary pilot study results revealed failure of the pilot study to demonstrate the outcomes as defined in the success criteria, and Novartis has requested a refund of the $900,000 milestone payment which is included in accrued expenses on the accompanying balance sheet. We received the final, detailed report of the pilot study from Novartis and are in the process of reviewing it. Novartis has indicated that they would defer the refund request until we have had an opportunity to review the final report. We plan to work with Novartis to obtain additional information and understand the implications of the pilot study results on product development efforts under the Novartis License Agreement.

In 2004, the Company entered into an agreement with WU, under which the Company obtained exclusive proprietary rights to WU’s patent portfolio for use in the animal health industry. The Exclusive License Agreement (WU License Agreement) between AspenBio and WU was entered into effective May 1, 2004, and grants AspenBio an exclusive license and right to sublicense WU’s technology (as defined under the WU License Agreement) for veterinary products worldwide, except where such products are prohibited for export under U.S. laws. The term of the WU License Agreement continues until the expiration of the last of WU’s patents (as defined in the WU License Agreement) to expire. AspenBio has agreed to pay minimum annual royalties of $20,000 during the term of the WU License Agreement and such amounts are creditable against future royalties. Royalties payable to WU under the WU License Agreement for covered product sales by AspenBio carry a mid-single digit royalty rate and sublicense fees received by AspenBio, carry a low double-digit royalty rate. The WU License Agreement contains customary terms for confidentiality, prosecution and infringement provisions for licensed patents, publication rights, indemnification and insurance coverage. The WU License Agreement is cancelable by AspenBio with ninety days advance notice at any time and by WU with sixty days advance notice if AspenBio materially breaches the WU License Agreement and fails to cure such breach. Under the terms of the WU License Agreement, a portion of license fees and royalties AspenBio receives from sublicensing agreements will be paid to WU. The obligation for such front end fees, totaling $440,000, was recorded upon receipt of the Novartis license fees and, in 2008; $190,000 was paid to WU.

For financial reporting purposes, the up-front license fees received from the Novartis License Agreement, net of the amounts due to WU, have been recorded as deferred revenue and are amortized over the term of the Novartis License Agreement. Milestone revenue is or will be recognized into income commencing with the date such milestones are achieved. During the year ended December 31, 2010, milestones totaling $100,000 associated with Novartis’ evaluation of additional products were achieved, triggering the commencement of amortization of $100,000 of deferred revenue. As of June 30, 2011, deferred revenue of $71,000 has been classified as a current liability and $598,000 has been classified as a long-term liability. The current liability includes the next twelve months’ portion of the amortizable milestone revenue. During each of the six months ended June 30, 2011 and 2010, approximately $36,000 and $33,000 was recorded as the amortized license fee revenue arising from the Novartis License Agreement.

We have entered and expect to continue to enter into additional agreements with contract manufacturers for the development / manufacture of certain of our products for which we are seeking FDA approval. The goal of this development process is to establish current good manufacturing practices (cGMP) required for those products for which we are seeking FDA approval. These development and manufacturing agreements generally contain transfer fees and possible penalty and /or royalty provisions should we transfer our products to another contract manufacturer. We expect to continue to evaluate, negotiate and execute additional and expanded development and manufacturing agreements, some of which may be significant commitments during 2011. We may also consider acquisitions of development technologies or products, should opportunities arise that we believe fit our business strategy and would be appropriate from a capital standpoint.

The Company periodically enters into generally short-term consulting and development agreements primarily for product development, testing services and in connection with clinical trials conducted as part of the Company’s FDA clearance process. Such commitments at any point in time may be significant but the agreements typically contain cancellation provisions.

We have a permanent mortgage facility on our land and building that commenced in July 2003. The mortgage is held by a commercial bank and includes a portion guaranteed by the U. S. Small Business Administration. The loan is collateralized by the real property and is also personally guaranteed by a stockholder (our former president). The interest rate on the bank portion is one percentage over the Wall Street Journal Prime Rate (minimum 7%), with 7% being the approximate effective rate, and the SBA portion bears interest at the rate of 5.86%. The commercial bank portion of the loan requires total monthly payments of approximately $14,200, which includes approximately $9,800 per month in contractual interest, through June 2013 when the then remaining principal balance is due which is estimated to be approximately $1,607,000 at that time. The SBA portion of the loan requires total monthly payments of approximately $9,200 through July 2023, which includes approximately $4,400 per month in contractual interest and fees.

In April 2008, the Board authorized a stock repurchase plan to purchase shares of our common stock up to a maximum of $5.0 million. Purchases may be made in routine, open market transactions, when management determines to effect purchases and any purchased shares of common stock are thereupon retired. Management may elect to purchase less than $5.0 million. The repurchase program allows us to repurchase our shares in accordance with the requirements of the Securities and Exchange Commission on the open market, in block trades and in privately negotiated transactions, depending upon market conditions and other factors. A total of approximately 46,400 common shares were purchased and retired in 2008 at a total cost of approximately $992,000. No repurchases have been made since 2008.

With the recent changes in market conditions, combined with our conservative investment policy and lower average investable balances due to cash consumption, we expect that our investment earnings in 2011 will be lower than in 2010. The Board of Directors has approved an investment policy covering the investment parameters to be followed with the primary goals being the safety of principal amounts and maintaining liquidity of the fund. The policy provides for minimum investment rating requirements as well as limitations on investment duration and concentrations. Commencing in the fourth quarter of 2008, based upon market conditions, the investment guidelines were tightened to raise the minimum acceptable investment ratings required for investments and shorten the maximum investment term. Current investment guidelines require investments to be made in investments with minimum ratings purchasing commercial paper with an A1/P1 rating, longer-term bonds with an A- rating or better, a maximum maturity of nine months and a concentration guideline of 10% (no security or issuer representing more than 10% of the portfolio). As of June 30, 2011, 83% of the investment portfolio was in cash equivalents which are included with cash and the remaining funds were invested in short term marketable securities with none individually representing more than 10% of the portfolio and none maturing past June 2012. To date, we have not experienced a cumulative market loss from the investments that has exceeded $5,000.

Due to recent market events that have adversely affected all industries and the economy as a whole, management has placed increased emphasis on monitoring the risks associated with the current environment, particularly the investment parameters of the short term investments, the recoverability of current assets, the fair value of assets, and the Company’s liquidity. At this point in time, there has not been a material impact on the Company’s assets and liquidity. Management will continue to monitor the risks associated with the current environment and their impact on the Company’s results.

Operating Activities

Net cash consumed by operating activities was $4,347,000 during the six months ended June 30, 2011. Cash was consumed by the loss of $5,593,000, less non-cash expenses of $675,000 for stock-based compensation and $277,000 for depreciation, amortization and impairment charges. For the six months ended June 30, 2011, decreases in inventories and accounts receivable generated cash of $67,000. A decrease in prepaid and other current assets of $183,000 provided cash, primarily related to routine changes in operating activities. Cash was generated due to a $718,000 increase in accounts payable and accrued expenses in the six months ended June 30, 2011 and offset by a decrease of $675,000 in the deferred revenue, primarily due to the reclassification of the deferred revenue under the Novartis agreement.

Net cash consumed by operating activities was $6,446,000 during the six months ended June 30, 2010. Cash was consumed by the loss of $7,294,000, less non-cash expenses of $1,320,000 for stock-based compensation and $258,000 for depreciation and amortization, impairment and other non-cash items. For the six months ended June 30, 2010, decreases in accounts receivable and inventories generated cash of $26,000 and $64,000, respectively. A net decrease of $832,000 in accounts payable and accrued expenses consumed cash in operating activities.

Investing Activities

Net cash inflows from investing activities generated $1,770,000 during the six months ended June 30, 2011. Marketable securities investments acquired totaled approximately $313,000 and sales of marketable securities totaled approximately $2,293,000. A $210,000 use of cash was attributable to additional costs incurred from patent filings and equipment additions.

Net cash outflows from investing activities generated $3,750,000 during the six months ended June 30, 2010. Net purchases of marketable securities investments acquired totaled approximately $3,364,000. A $386,000 use of cash was attributable to additional costs incurred from patent filings and equipment additions.

Financing Activities

Net cash outflows from financing activities consumed $223,000 during the six month period ended June 30, 2011 for repayments under existing debt agreements.

Net cash inflows from financing activities generated $9,353,000 during the six month period ended June 30, 2010. The Company received net proceeds of $9,117,000 from the issuance of common stock and $291,000 in proceeds from the exercise of stock warrants and options. The Company repaid $54,000 in scheduled payments under its debt agreements.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and accompanying notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment. Actual results inevitably will differ from those estimates, and such differences may be material to the financial statements. The most significant accounting estimates inherent in the preparation of our financial statements include estimates associated with revenue recognition, impairment analysis of intangibles and stock-based compensation.

The Company’s financial position, results of operations and cash flows are impacted by the accounting policies the Company has adopted. In order to get a full understanding of the Company’s financial statements, one must have a clear understanding of the accounting policies employed. A summary of the Company’s critical accounting policies follows:

Investments: The Company invests excess cash from time to time in highly liquid debt and equity securities of highly rated entities which are classified as trading securities. Such amounts are recorded at market and are classified as current, as the Company does not intend to hold the investments beyond twelve months. Such excess funds are invested under the Company’s investment policy but an unexpected decline or loss could have an adverse and material effect on the carrying value, recoverability or investment returns of such investments. The Board has approved an investment policy covering the investment parameters to be followed with the primary goals being the safety of principal amounts and maintaining liquidity of the fund. The policy provides for minimum investment rating requirements as well as limitations on investment duration and concentrations.

Long-Lived Assets: The Company records property and equipment at cost. Depreciation of the assets is recorded on the straight-line basis over the estimated useful lives of the assets. Dispositions of property and equipment are recorded in the period of disposition and any resulting gains or losses are charged to income or expense when the disposal occurs. The carrying value of the Company’s long-lived assets is reviewed at least annually to determine that such carrying amounts are not in excess of estimated market value. Goodwill is reviewed annually for impairment by comparing the carrying value to the present value of its expected cash flows or future value. The required annual testing resulted in no impairment charges being recorded to date.

Revenue Recognition: The Company’s revenues are recognized when products are shipped or delivered to unaffiliated customers. The Securities and Exchange Commission’s Staff Accounting Bulletin (SAB) No. 104, provides guidance on the application of generally accepted accounting principles to select revenue recognition issues. The Company has concluded that its revenue recognition policy is appropriate and in accordance with SAB No. 104. Revenue is recognized under development and distribution agreements only after the following criteria are met: (i) there exists adequate evidence of the transactions; (ii) delivery of goods has occurred or services have been rendered; and (iii) the price is not contingent on future activity and collectability is reasonably assured.

Stock-based Compensation: ASC 718 (formerly - SFAS No. 123(R)), Share-Based Payment, defines the fair-value-based method of accounting for stock-based employee compensation plans and transactions used by the Company to account for its issuances of equity instruments to record compensation cost for stock-based employee compensation plans at fair value as well as to acquire goods or services from non-employees. Transactions in which the Company issues stock-based compensation to employees, directors and advisors and for goods or services received from non-employees are accounted for based on the fair value of the equity instruments issued. The Company utilizes pricing models in determining the fair values of options and warrants issued as stock-based compensation. These pricing models utilize the market price of the Company’s common stock and the exercise price of the option or warrant, as well as time value and volatility factors underlying the positions.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION AND STATEMENTS

Certain statements in Management’s Discussion and Analysis and other portions of this report are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology. Please see the “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2010, as amended, for a discussion of certain important factors that relate to forward-looking statements contained in this report. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

General

AspenBio has limited exposure to market risks from instruments that may impact the Balance Sheets, Statements of Operations, and Statements of Cash Flows, with such exposure associated primarily with changing interest rates on its mortgage notes and investments. Approximately 35% of the total mortgage balance is guaranteed by the U. S. Small Business Administration (“SBA”). While we periodically expend funds for products and services that are denominated in foreign country currencies we do not have any long term commitments for such purchases.

Investment Interest Rates

The primary objective for our investment activities is to preserve principal while maximizing yields without significantly increasing risk. This is accomplished by investing in diversified short-term interest bearing investments of high grade companies. We have no investments denominated in foreign country currencies and therefore our investments are not subject to foreign currency exchange risk.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Management of the Company, including the Chief Executive Officer and the Chief Financial Officer, has conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rule 13a-15(e)) as of the last day of the period of the accompanying financial statements. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of June 30, 2011.

Changes in Internal Control Over Financial Reporting.

There was no change in the Company’s internal control over financial reporting that occurred during the fiscal quarter to which this report relates that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

On September 1, 2010, the Company received a complaint, captioned Mark Chipman v. AspenBio Pharma, Inc., Case No. 2:10-cv-06537-GW-JC. The complaint was filed in the United States District Court in the Central District of California by an individual investor. The complaint includes allegations of fraud, negligent misrepresentation, violations of Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”) and Securities and Exchange Commission (“SEC”) Rule 10b-5, and violations of Sections 25400 and 25500 of the California Corporations Code, all related to the Company’s blood-based acute appendicitis test in development known as AppyScore. On the Company’s motion, the action was transferred to the U.S. District Court for the District of Colorado by order dated January 21, 2011. The action has been assigned a District of Colorado Civil Case No. 11-cv-00163-REB-KMT. Based on a review of the currently operative complaint, the Company believes that the plaintiff’s allegations are without merit, and intends to vigorously defend against these claims. The plaintiff may file an amended complaint on or about August 10, 2011, after which time the Company anticipates filing a motion to dismiss the case. If the plaintiff does not file an amended complaint, the Company expects that it will renew its pending motion to dismiss.

We are not a party to any other legal proceedings, the adverse outcome of which would, in our management’s opinion, have a material adverse effect on our business, financial condition and results of operations.

Item 1A. Risk Factors

There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2010.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a) During the quarter covered by this report, the Company did not make any purchases of its common shares under the previously announced authorized common stock repurchase program of up to $5 million that may be made from time to time at prevailing prices as permitted by securities laws and other requirements and subject to market conditions and other factors and no purchases are anticipated in the near-term. The program is administered by management and may be discontinued at any time.

Item 6. Exhibits

(a) Exhibits

EXHIBIT

DESCRIPTION

3	Amendment to Articles of Incorporation (1)

10.1	Amendment to Amended and Restated 2002 Stock Incentive Plan as Amended, dated July 8, 2011 (2)

31.1	Rule 13a-14(a)/15d-14(a) - Certification of Chief Executive Officer. Filed herewith.

31.2	Rule 13a-14(a)/15d-14(a) - Certification of Chief Financial Officer. Filed herewith.

32	Section 1350 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the SARBANES-OXLEY ACT of 2002. Furnished herewith.

101	Interactive data files pursuant to Rule 405 of Regulation S-T: (i) the Balance Sheets, (ii) the Statements of Operations, (iii) the Statement of Cash Flows and (iv) the Notes to Condensed Financial Statements. (3)

(1)	Incorporated by reference from the registrant’s report on Form 8-K filed on July 29, 2011.

(2)	Incorporated by reference from the registrant’s report on Form 8-K filed on July 13, 2011.

(3)	Pursuant to Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall not be deemed to be filed by the Company for purposes of Section 18 or any other provision of the Exchange Act of 1934, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AspenBio Pharma, Inc. (Registrant)
	By:	/s/ Jeffrey G. McGonegal
Dated: August 9, 2011		Jeffrey G. McGonegal, Chief Financial Officer and duly authorized officer